Schmid Maximilian P, Held Thomas, Lang Kristin, Herfarth Klaus, Hörner-Rieber Juliane, Harrabi Semi B, Moratin Julius, Freudlsperger Christian, Zaoui Karim, Debus Jürgen, Adeberg Sebastian
Heidelberg Ion-Beam Therapy Center, Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Department of Radiation Oncology-Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Cancers (Basel). 2021 Jan 2;13(1):124. doi: 10.3390/cancers13010124.
: to report clinical outcome in patients with acinic cell carcinoma of the salivary glands treated with intensity-modulated radiotherapy (IMRT) and carbon ion radiotherapy (CIRT) boost. : all patients with acinic cell carcinoma of the salivary glands treated at the Heidelberg Ion-Beam Therapy Center were considered for this retrospective analysis. All patients received a CIRT boost with 18-24 Gy radiobiologic effectiveness (RBE)-weighted dose in 3 Gy RBE-weighted dose per fraction followed by IMRT, with 50-54 Gy in 2 Gy per fraction. Disease outcome was evaluated for local (LR), nodal (NR), distant recurrence (DR), and disease-free (DFS) and overall survival (OS). Morbidity was scored based on Common Terminology Criteria for Adverse Events (CTCAE) version 5. Descriptive statistics and the Kaplan-Meier method were used for analysis. : fifteen patients were available for analysis. Median follow-up after radiotherapy was 43 months. Six patients were treated for primary disease and nine for recurrent disease. Eight patients were treated with radiotherapy for macroscopic disease. Disease recurrence was observed in four patients: 1 LR, 2 NR, and 2 DR; 5-year local control, DFS, and OS were 80%, 52%, and 80%, respectively. No radiotherapy-related G3-5 morbidity was observed. : In acinic cell carcinoma, IMRT with carbon ion radiotherapy boost leads to excellent results after R1-resection and is a promising treatment modality for definitive treatment in inoperable patients.
报告接受调强放疗（IMRT）和碳离子放疗（CIRT）增敏治疗的涎腺腺泡细胞癌患者的临床结局。：海德堡离子束治疗中心治疗的所有涎腺腺泡细胞癌患者均纳入本回顾性分析。所有患者先接受CIRT增敏，给予18 - 24 Gy的放射生物学效应（RBE）加权剂量，每次分割剂量为3 Gy RBE加权剂量，随后接受IMRT，每次分割剂量为2 Gy，总剂量为50 - 54 Gy。评估疾病结局包括局部复发（LR）、区域复发（NR）、远处复发（DR）、无病生存（DFS）和总生存（OS）。根据不良事件通用术语标准（CTCAE）第5版对不良反应进行评分。采用描述性统计和Kaplan - Meier方法进行分析。：15例患者可供分析。放疗后的中位随访时间为43个月。6例患者治疗原发性疾病，9例治疗复发性疾病。8例患者因肉眼可见的疾病接受放疗。4例患者出现疾病复发：1例局部复发，2例区域复发，2例远处复发；5年局部控制率、无病生存率和总生存率分别为80%、52%和80%。未观察到与放疗相关的3 - 5级不良反应。：在腺泡细胞癌中，IMRT联合碳离子放疗增敏在R1切除术后可取得优异结果，对于无法手术的患者是一种有前景的确定性治疗方式。
